<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446016</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00006423</org_study_id>
    <secondary_id>0811-0147</secondary_id>
    <nct_id>NCT01446016</nct_id>
  </id_info>
  <brief_title>Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)</brief_title>
  <acronym>CAT</acronym>
  <official_title>Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jenny C. Chang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this research study is to better understand how therapy works on&#xD;
      different patients. This study is being offered to patients with a diagnosis of advanced or&#xD;
      metastatic breast cancer who have failed anthracycline based therapy.&#xD;
&#xD;
      The investigators want to see the response of breast cancer cell when treated with&#xD;
      Chloroquine used in combination with chemotherapy. Chemotherapy is an anti-cancer drug that&#xD;
      is given through your vein. The chemotherapy used in this study is either Taxane (Paclitaxel)&#xD;
      or Taxane-like drugs (Abraxane, Ixabepilone or Docetaxel).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the anti-tumor activity of the combination of&#xD;
      Chloroquine combined with a Taxane or Taxane-like chemo agents(Paclitaxel, Docetaxel,&#xD;
      Abraxane, Ixabepilone).&#xD;
&#xD;
      The laboratories have developed robust preclinical models utilizing both in vitro systems&#xD;
      such as the mammosphere (MS) culture and in vivo systems such as human breast cancer&#xD;
      xenografts allowing the investigators to identify agents which selectively target TICs, as&#xD;
      single agents or in combination. These models are critical since tumor initiating cells&#xD;
      (TICs) comprise only a small percentage of the tumor bulk, so that clinical tumor regression&#xD;
      may not be observed with inhibitors that selectively target TIC self-renewal alone.&#xD;
      Nonetheless, these agents in combination with conventional therapy may effectively kill both&#xD;
      actively cycling or fully differentiated cells and the TIC subpopulation, leading to long&#xD;
      term remission and eradication of cancer cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>One Year</time_frame>
    <description>To determine the anti-tumor activity of the combination of Chloroquine + Taxane or Taxane-like chemo agents (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) (C/T) measured by overall Response Rate (ORR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>One Year</time_frame>
    <description>To assess the safety and tolerability of the combination of Chloroquine and Taxane or Taxane-Like chemo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Control Rate</measure>
    <time_frame>One Year</time_frame>
    <description>To assess the response rate and tumor control rate (TCR) of patients receiving Chloroquine + Taxane or Taxane-like.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>One Year</time_frame>
    <description>To assess the Time to Progression (TTP) of patients receiving Chloroquine + Taxane or Taxane-like chemo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Three Years</time_frame>
    <description>To assess the duration of response (DOR) of patients receiving Chloroquine + Taxane or Taxane-like chemo agents.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Taxane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxane-Like</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane</intervention_name>
    <description>Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.</description>
    <arm_group_label>Taxane</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks</description>
    <arm_group_label>Taxane-Like</arm_group_label>
    <other_name>Taxne-like</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.</description>
    <arm_group_label>Taxane-Like</arm_group_label>
    <other_name>Taxane-like</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <description>Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.</description>
    <arm_group_label>Taxane-Like</arm_group_label>
    <other_name>Taxane-like</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females with pathologically determined advanced or metastatic breast cancer.&#xD;
&#xD;
          2. Have progressed after treatment with regimen that included an anthracycline.&#xD;
&#xD;
          3. Have had at least 4 cycles of an anthracycline containing regimen or 2 cycles if&#xD;
             progressing on treatment.&#xD;
&#xD;
          4. Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors.&#xD;
&#xD;
          5. ≥18 years of age.&#xD;
&#xD;
          6. ECOG PS of 0, 1, or 2.&#xD;
&#xD;
          7. Laboratory values within the following ranges:&#xD;
&#xD;
               -  Hemoglobin ≥9.0gm/dL (≥1.5μmol/L); transfusions permitted.&#xD;
&#xD;
               -  Absolute neutrophil count ≥1500/mm3 (1.5 x 109/L)&#xD;
&#xD;
               -  Platelet count ≥100,000/mm3 (100 x 109/L)&#xD;
&#xD;
               -  Creatinine (Cr) &lt;2 X the upper limit of normal (ULN), Cr clearance (CrCl) ≥30 by&#xD;
                  Cockcroft and Gault&#xD;
&#xD;
               -  Alanine aminotransferase and aspartate aminotransferase &lt;2 X the ULN; if liver&#xD;
                  metastases are present then must be &lt;5 X the ULN, Bilirubin &lt;2 X the ULN,&#xD;
                  Potassium within normal limits, Magnesium within normal limits&#xD;
&#xD;
          8. Negative serum pregnancy test at the time of first dose for women of childbearing&#xD;
             potential (WOCBP). For WOCBP, adequate contraception must be used throughout the&#xD;
             study. For this study, acceptable methods of contraception include a reliable&#xD;
             intrauterine device or a spermicide in combination with a barrier method. Women who&#xD;
             are already on hormonal forms of birth control may continue that treatment but must&#xD;
             also use a barrier method.&#xD;
&#xD;
          9. Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and return for the required assessments.&#xD;
&#xD;
         10. Patient must be willing to undergo breast biopsies as required by the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiation therapy within 2 weeks; or chemotherapy or non-cytotoxic investigational&#xD;
             agents within 4 weeks of initiating study treatment.&#xD;
&#xD;
          2. Evidence of New York Heart Association class III or greater cardiac disease.&#xD;
&#xD;
          3. History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic&#xD;
             conduction abnormality within 12 months.&#xD;
&#xD;
          4. History of congenital QT prolongation.&#xD;
&#xD;
          5. QT &gt;500.&#xD;
&#xD;
          6. Concurrent severe or uncontrolled medical disease (i.e., active systemic infection,&#xD;
             diabetes, hypertension, coronary artery disease, congestive heart failure) that, in&#xD;
             the opinion of the Investigator, would compromise the safety of the patient or&#xD;
             compromise the ability of the patient to complete the study.&#xD;
&#xD;
          7. Symptomatic central nervous system metastases. The patient must be stable after&#xD;
             radiotherapy for ≥2 weeks and off corticosteroids for ≥1 week.&#xD;
&#xD;
          8. Pregnant or nursing women.&#xD;
&#xD;
          9. Hypersensitivity or intolerance to Chloroquine, Paclitaxel, Docetaxel, Abraxane,&#xD;
             Ixabepilone or other Taxane like drugs.&#xD;
&#xD;
         10. Severe renal insufficiency (CrCl &lt;30mL/min [Cockcroft and Gault]).&#xD;
&#xD;
         11. History of gastrointestinal bleeding, ulceration, or perforation.&#xD;
&#xD;
         12. Concurrent use of potent CYP3A4 inhibitors, such as ketoconazole,&#xD;
             itraconazole,clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,&#xD;
             telithromycin, and voriconazole.&#xD;
&#xD;
         13. Concurrent use of potent CYP3A4 inducers, such as dexamethasone, phenytoin,&#xD;
             carbamazepine, rifampin, rifabutin, rifapentine, phenobarbitol, and St. John's wort.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny C Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Willowbrook</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Jenny C. Chang, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator/Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Human Mammary Carcinoma</keyword>
  <keyword>Mammary Carcinoma, Human</keyword>
  <keyword>Mammary Neoplasm, Human</keyword>
  <keyword>Mammary Neoplasms, Human</keyword>
  <keyword>Neoplasms, Breast</keyword>
  <keyword>Tumors, Breast</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>Abraxane</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Anthracycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>May 6, 2021</submitted>
    <returned>May 28, 2021</returned>
    <submitted>July 5, 2021</submitted>
    <returned>July 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

